Apart from the well-studied EGFR-STAT3 signaling, we identified a novel regulatory axis, namely STAT3/CXCL1, in IGFBP2-enhanced gefitinib resistance in NSCLC. Here, IGFBP2 is linked to non-small cell lung carcinoma.